The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare genetic disorder, making it the company’s first wholly-owned drug, the health regulator’s website showed on Thursday.
Submission of the Biologics License Application seeks approval of lerodalcibep to lower LDL-C in patients with or at risk for ASCVD and primary hyperlipidemia.
FREE GIVEAWAY OF JENSEN-HUANG-SIGNED ORIN NANO SUPER! See Below!Join Dave as he explores NVIDIA’s Jetson Orin Nano, a compact AI powerhouse with 1024 CUDA c…
GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance therapy improved survival in patients with…
The Federal Aviation Administration has now issued bans on flying drones in multiple cities across New Jersey, including several locations in our area, due to…
“We’ve had two years of runway — pretty much uncontested,” Nadella told the “BG2Pod with Brad Gerstner and Bill Gurley.”
“Genesis” can compress training times from decades into hours using 3D worlds conjured from text.
This e-book provides information about the advantages and disadvantages of different activity tracking solutions in research use. The guide is not a systematic review but…
Using descriptions of flavours or chemical data, artificial intelligence can tell apart whiskies from different countries and identify their constituent aromas
The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals’ drug to treat a rare genetic disorder, making it the company’s first wholly-owned drug, the…
An aide-memoire for the care of people living with T2D, highlighting recommendations and resources to facilitate a holistic approach in primary care
